Feasibility and acceptability of using the novel urine-based FujiLAM test to detect tuberculosis: A multi-country mixed-methods study.
Diagnostic tests
Feasibility studies
FujiLAM
Low income settings
Tuberculosis
Journal
Journal of clinical tuberculosis and other mycobacterial diseases
ISSN: 2405-5794
Titre abrégé: J Clin Tuberc Other Mycobact Dis
Pays: England
ID NLM: 101682877
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
entrez:
6
5
2022
pubmed:
7
5
2022
medline:
7
5
2022
Statut:
epublish
Résumé
The novel urine-based FujiLAM test identifies tuberculosis in HIV-positive patients but may be challenging to use at point-of-care (POC). We assessed the feasibility and acceptability of using the FujiLAM test at point of care in outpatient settings. We conducted a mixed methods study in four outpatient settings in Kenya, Mozambique, South Africa, and Uganda between November 2020 and September 2021. The test was performed at POC in existing clinic laboratories and consultation spaces. We performed direct observations in the four health facilities, individual questionnaires, proficiency testing evaluations, and individual interviews among healthcare workers performing the FujiLAM test (healthcare workers), and group discussions with programme managers. Overall, 18/19 (95%) healthcare workers and 14/14 (100%) managers agreed to participate in the study. Most assessed healthcare workers, including lay health workers (10/11; 91%), met the minimum required theoretical knowledge and practical skill in performing the FujiLAM test. Most healthcare workers (17/18; 94%) found the FujiLAM test overall " Implementing the FujiLAM test in outpatient POC settings is feasible and acceptable to healthcare workers and managers. This test can be performed in various clinic locations by any healthcare worker. The timed, multi-step test procedure is challenging and may affect the workload in resource-constrained health facilities.
Sections du résumé
Background
UNASSIGNED
The novel urine-based FujiLAM test identifies tuberculosis in HIV-positive patients but may be challenging to use at point-of-care (POC).
Objectives
UNASSIGNED
We assessed the feasibility and acceptability of using the FujiLAM test at point of care in outpatient settings.
Methods
UNASSIGNED
We conducted a mixed methods study in four outpatient settings in Kenya, Mozambique, South Africa, and Uganda between November 2020 and September 2021. The test was performed at POC in existing clinic laboratories and consultation spaces. We performed direct observations in the four health facilities, individual questionnaires, proficiency testing evaluations, and individual interviews among healthcare workers performing the FujiLAM test (healthcare workers), and group discussions with programme managers.
Results
UNASSIGNED
Overall, 18/19 (95%) healthcare workers and 14/14 (100%) managers agreed to participate in the study. Most assessed healthcare workers, including lay health workers (10/11; 91%), met the minimum required theoretical knowledge and practical skill in performing the FujiLAM test. Most healthcare workers (17/18; 94%) found the FujiLAM test overall "
Conclusions
UNASSIGNED
Implementing the FujiLAM test in outpatient POC settings is feasible and acceptable to healthcare workers and managers. This test can be performed in various clinic locations by any healthcare worker. The timed, multi-step test procedure is challenging and may affect the workload in resource-constrained health facilities.
Identifiants
pubmed: 35521634
doi: 10.1016/j.jctube.2022.100316
pii: S2405-5794(22)00021-3
pmc: PMC9065638
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100316Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Gates Open Res. 2020 Feb 13;4:24
pubmed: 32185366
Cochrane Database Syst Rev. 2019 Oct 21;10:CD011420
pubmed: 31633805
Glob Health Action. 2019;12(1):1672366
pubmed: 31610754
J Infect Dis. 2011 Nov 15;204 Suppl 4:S1159-67
pubmed: 21996698
Malar J. 2016 Feb 05;15:64
pubmed: 26850000
Lancet Infect Dis. 2012 Mar;12(3):201-9
pubmed: 22015305
PLoS One. 2015 Nov 25;10(11):e0143075
pubmed: 26605800
Lancet Infect Dis. 2019 Aug;19(8):852-861
pubmed: 31155318
Clin Infect Dis. 2021 Nov 2;73(9):e3428-e3434
pubmed: 33388751
PLoS One. 2013 Oct 29;8(10):e77456
pubmed: 24204834
Clin Infect Dis. 2006 Feb 1;42(3):377-82
pubmed: 16392084
BMJ Open. 2014 Mar 03;4(3):e004093
pubmed: 24589822
Int J Infect Dis. 2021 Nov;112:237-242
pubmed: 34525399
J Adv Nurs. 2008 Apr;62(1):107-15
pubmed: 18352969
J Clin Invest. 2020 Nov 2;130(11):5756-5764
pubmed: 32692731
PLoS One. 2017 Jan 26;12(1):e0170976
pubmed: 28125693
Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
Afr J Lab Med. 2017 Sep 18;6(1):643
pubmed: 29159139
Am J Clin Pathol. 2010 Sep;134(3):374-80
pubmed: 20716792
Eur Respir J. 2012 Nov;40(5):1211-20
pubmed: 22362849
Cochrane Database Syst Rev. 2016 May 10;(5):CD011420
pubmed: 27163343
Malar J. 2010 Apr 23;9:109
pubmed: 20412600
PLoS Med. 2019 Apr 30;16(4):e1002792
pubmed: 31039161
Health Serv Res. 2013 Dec;48(6 Pt 2):2134-56
pubmed: 24279835
J Virus Erad. 2018 Jan 1;4(1):12-15
pubmed: 29568547